MRVI - Mergers and acquisitions

Molecular Assemblies proprietary Fully Enzymatic SynthesisTM technology to enhance mRNA and oligonucleotide manufacturing capabilities within the TriLink BioTechnologies business Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today its acquisition of intellectual property and relevant assets from Molecular Assemblies (MAI). The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies. "Molecular Assemblies is the original leader in enzymatic oligo synthesis, with strong foundational IP.

MyChem's nucleotide synthesis methods are highly complementary to Maravai's TriLink mRNA technologies Increases capabilities serving the high-growth cell and gene therapy market SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has acquired MyChem, LLC for $240 million in cash at closing with the potential for additional contingent cash consideration based on achievement of certain conditions after closing. The acquisition will expand Maravai's product offering of strategic inputs in the rapidly growing markets for therapeutics and va

Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced it has acquired Vector Laboratories, the Protein Detection business unit of Maravai (NASDAQ:MRVI). Vector Laboratories is a manufacturer of labeling and visual detection reagents for life science researchers doing tissue-based protein detection and characterization. The acquisition of Vector adds to TSCP's experience in life sciences. "Maravai has been critical in helping strengthen Vector Laboratories' operations, including innovative solutions to better serve our academic and early development stage customers," said Lisa V. Sellers, Ph.D., Vector's Chief Executive Officer. "We're excited to partn